The molecular background of the Ca2+-sensitizing effect of levosimendan relates to its
specific interaction with the Ca2+-sensor troponin C molecule in the cardiac myofilaments …

Objective: Catecholaminergic inotropes have a place in the management of low output
syndrome and decompensated heart failure but their effect on mortality is debated …

Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for
decompensated heart failure (HF) patients with low cardiac output. Accumulated evidence …

What is known and objective Positive inotropic agents are frequently used in acute
decompensated heart failure (ADHF) due to left ventricular systolic dysfunction. These …

Levosimendan is a new calcium sensitizer and K-ATP channel opener. Compared with other
inodilators, it improves myocardial contractility without increasing oxygen requirements and …

Cardiogenic shock is the most common cause of death in patients hospitalized with acute
myocardial infarction and is associated with a poor prognosis. More than 75% of cases are …

BACKGROUND: Istaroxime is a novel intravenous agent with inotropic and lusitropic
properties related to inhibition of the Na+/K+ adenosine triphosphatase and stimulation of …

Levosimendan has been developed for the treatment of decompensated heart failure and is
used intravenously when patients with heart failure require immediate initiation of drug …

Endotoxemia induces a hemodynamic form of acute renal failure (ARF; renal
vasoconstriction±reduced glomerular ultrafiltration coefficient, K f; minimal/no histological …

The use of inotropes for correcting hemodynamic dysfunction in patients with congestive
heart failure has been described over many decades. Drugs such as cardiac glycosides …